Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy

NDA FilingOpamtistomigPositive

AI Analysis

Summary

Leads Biolabs announced that the NMPA's Center for Drug Evaluation has accepted the NDA for Opamtistomig, a PD-L1/4-1BB bispecific antibody that could become the world's first approved 4-1BB-targeting therapy. The acceptance marks a significant milestone in the regulatory pathway for this immunotherapy candidate in China.

Outcome Details

NDA accepted by NMPA Center for Drug Evaluation

Importance:7/10

Sentiment:

0.80

NDA_AcceptanceChina_RegulatoryImmunotherapyFirst-in-Class_Potential4-1BB_Pathway

Related Companies

$NHPAP $MDCE $CHHE $TRAX $WHEN

Read the original article

Published by PR Newswire Biotech on August 21, 2026 9:20 AM

Read Original